A double-blind, placebo-controlled randomized trial of creatine for the cancer anorexia/weight loss syndrome (N02C4): an Alliance trial
Jatoi A, Steen PD, Atherton PJ, Moore DF, Rowland KM, Le-Lindqwister NA, Adonizio CS, Jaslowski AJ, Sloan J, Loprinzi C
Annals of oncology : official journal of the European Society for Medical Oncology · 31 citas
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación independiente
- Gobierno
- National Institutes of Health
- Gobierno
- National Cancer Institute
- Gobierno
- NCI NIH HHS
- Subvenciones
- National Cancer Institute (UG1 CA189823); National Cancer Institute (UG1 CA189861)
Según 3 financiadores declarados.
Publicación
- Publicado
- 2017-05-04 · Ann Oncol · vol. 28 · número 8 · págs. 1957–1963
- Editorial
- Elsevier BV
- Citado
- 38 citas · más que el 85% de estudios similares · 1.9× el promedio de su campo
- Referencias
- 23 trabajos
- Acceso
- Lectura gratuita
- Áreas de investigación
- Nutrition and Health in Aging · Clinical Nutrition and Gastroenterology · Muscle metabolism and nutrition
- Palabras clave
- creatine supplementation, cachexia, weight gain, muscle strength, body composition, appetite, quality of life, survival
- MeSH
- humans, neoplasms, weight loss, anorexia, creatine, placebos, double-blind method, aged, middle aged, female, male
10 autores
- Aminah Jatoi🇺🇸 · autor de correspondenciaMayo Clinic
- Preston D. Steen🇺🇸Sanford Health
- Philip James Atherton🇺🇸Mayo Clinic
- Dennis Frederic Moore🇺🇸Wichita Clinic
- Kendrith M. Rowland🇺🇸Carle Foundation Hospital
- Nguyet Anh Le-Lindqwister
- Christian S. Adonizio🇺🇸Geisinger Medical Center
- Anthony John Jaslowski🇺🇸St. Vincent Hospital
- Jeff A. Sloan🇺🇸Mayo Clinic
- Charles L. Loprinzi🇺🇸Mayo Clinic
Resumen
El texto original del estudio, en el idioma en que se publicó.
Background
Multiple pilot studies, including one in colorectal cancer patients, suggest that creatine, an amino acid derivative, augments muscle, improves strength, and thereby could palliate the cancer anorexia/weight loss syndrome.
Patients and methods
In this randomized, double-blind, placebo-controlled trial, incurable patients with this syndrome were assigned creatine (20 g/day load×5 days followed by 2 g/day orally) versus identical placebo. Patients were weighed once a week for 1 month and then monthly. Patients were also assessed over 1 month for appetite and quality of life (validated questionnaires), fist grip strength, body composition (bioelectrical impedance), and adverse events. The primary endpoint was 10% or greater weight gain from baseline during the first month.
Results
Within this combined cohort of 263 evaluable patients (134 received creatine and 129 placebo), only 3 gained ≥10% of their baseline weight by 1 month: two creatine-treated and the other placebo-exposed (P = 1.00). Questionnaire data on appetite, quality of life, and activities of daily living showed no statistically significant differences between groups. Similarly, no statistically significant differences between groups were observed for fist-grip strength or body composition. Rates and severity of adverse events were comparable between groups. Finally, a median survival of 230 and 239 days were observed in the creatine and placebo groups, respectively (P = 0.70).
Conclusion
Creatine, as prescribed in this trial, had no effect on the cancer anorexia/weight loss syndrome.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.